Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02106208
Other study ID # INAF-2013-251
Secondary ID
Status Completed
Phase N/A
First received April 1, 2014
Last updated February 21, 2018
Start date April 2014
Est. completion date December 2017

Study information

Verified date February 2018
Source Laval University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Market trends depicted by Agriculture and Agri-Food Canada suggest stagnation in cheese consumption, with potentially important impact on this key industry in Canada. This is in part due to the commonly accepted notion that saturated fat in the diet, of which cheese contributes significantly, increases the risk of heart disease. Yet, a rather large body of recent evidence suggests that saturated fat may have been unfairly demonized and that its impact on the risk of heart disease may in fact be less important than originally thought. This concept that dairy fat increases the risk of heart attacks therefore needs to be revisited, and this is one of the key objectives of this proposed research program.

The proposed research is designed to investigate for the first time if dairy fat improves the levels of the so-called "good cholesterol", a protective risk factor that has been essentially ignored in the arguments supporting the reduction of saturated fat for heart health.

Our hypothesis is that consumption of SFA from dairy (cheese) compared with a low fat diet and diets rich in MUFA and PUFA leads to favorable changes in plasma HDL-C concentrations and functional characteristics. Consumption of SFA from dairy (cheese) also increases LDL particle size, reduces inflammation and has no deleterious impact on plasma LDL-C and apolipoproteins B (apoB) concentrations compared with a low fat diet.


Description:

This is a multi-center randomized crossover controlled feeding study. Briefly, adult men and women will be recruited in the Quebec City and Winnipeg metropolitan area through the media (newspaper, radio), local lipid clinics and mailing lists (n=90).

Participants will be randomized to a series of 5 experimental diets of 4 weeks each: 1- Cheese diet, 2- Butter diet, 3- Carbohydrate (CHO) diet, 4- MUFA diet, 5- PUFA diet. Usual energy intake will be estimated at the beginning of the study using validated tools. Experimental diets will be provided as part of a full feeding protocol under carefully controlled isocaloric conditions to maintain body weight constant. All meals and foods will be provided to participants so that control for energy and macronutrient intake will be optimized. The breakfast meal will represent approximately 30% of the daily energy intake whereas the lunch and dinner meals each will provide 35% of daily energy intake. Participants will be instructed to consume their entire meals. A seven-day cyclic menu will be used. The diets will be separated by washout periods of 4 weeks. Blood samples will be collected on two consecutive days before and after each dietary phase. The mean of the two consecutive measurements will be used in the analyses.


Recruitment information / eligibility

Status Completed
Enrollment 103
Est. completion date December 2017
Est. primary completion date June 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Men and women age between 18 and 65 years

- Waist circumference >80.0 cm for women and >94.0 cm for men

- Plasma concentration of triglycerides >1.70 mmol / L

- Stable weight for 6 months before the start of the study (+/- 5lbs)

Exclusion Criteria:

- Men or women aged under 18 years or over 65 years

- History of CVD, type 2 diabetes or dyslipidaemia monogenic

- Endocrine disorders

- Smoking

- Lipid lowering medications or hypertension medications

- Food allergies and aversions to any food in the composition of experimental menus

- Subjects with special dietary habits (e.g. vegetarianism)

- Subject with a calculated Framingham risk of cardiovascular disease (CVD) > 20%

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Cheese diet

Butter diet

CHO diet

MUFA diet

PUFA diet


Locations

Country Name City State
Canada Institute of Nutrition and Funtional Foods Quebec
Canada Richardson Centre for Functional Foods and Nutraceuticals Winnipeg Manitoba

Sponsors (3)

Lead Sponsor Collaborator
Laval University Agriculture and Agri-Food Canada, Dairy Farmers of Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in High-Density-Lipoproteins concentrations (HDL-C) Post-diet values will be compared; the primary analysis (pre-determined comparisons) are
Cheese vs Butter,
Cheese vs CHO, MUFA, PUFA
Butter vs. CHO, MUFA, PUFA
4 weeks (end-point value)
Secondary Change in HDL-C particle size and subclass Post-diet values will be compared; the primary analysis (pre-determined comparisons) are
Cheese vs Butter,
Cheese vs CHO, MUFA, PUFA
Butter vs. CHO, MUFA, PUFA
4 weeks (end-point value)
Secondary Change in HDL cholesterol efflux In a subset of individual;
Post-diet values will be compared; the primary analysis (pre-determined comparisons) are
Cheese vs Butter,
Cheese vs CHO, MUFA, PUFA
Butter vs. CHO, MUFA, PUFA
4 weeks (end-point value)
Secondary Change in Low Density Lipoproteins (LDL) particle size Post-diet values will be compared; the primary analysis (pre-determined comparisons) are
Cheese vs Butter,
Cheese vs CHO, MUFA, PUFA
Butter vs. CHO, MUFA, PUFA
4 weeks (end-point value)
Secondary Change in C-Reactive Proteins (CRP) concentrations Post-diet values will be compared; the primary analysis (pre-determined comparisons) are
Cheese vs Butter,
Cheese vs CHO, MUFA, PUFA
Butter vs. CHO, MUFA, PUFA
4 weeks (end-point value)
Secondary Change in adiponectin concentrations Post-diet values will be compared; the primary analysis (pre-determined comparisons) are
Cheese vs Butter,
Cheese vs CHO, MUFA, PUFA
Butter vs. CHO, MUFA, PUFA
4 weeks (end-point value)
See also
  Status Clinical Trial Phase
Recruiting NCT04635202 - Effect of Elliptical Training on Metabolic Homeostasis in Metabolic Syndrome N/A
Completed NCT04053686 - An Intervention to Reduce Prolonged Sitting in Police Staff N/A
Completed NCT05343858 - Pilot Study to Evaluate the Effect of Two Microalgae Consumption on Metabolic Syndrome N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Recruiting NCT05040958 - Carotid Atherosclerotic Plaque Load and Neck Circumference
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Completed NCT03289897 - Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan N/A
Recruiting NCT05956886 - Sleep Chatbot Intervention for Emerging Black/African American Adults N/A
Completed NCT06057896 - Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
Active, not recruiting NCT03613740 - Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion Phase 2
Completed NCT04498455 - Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency Phase 4
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT03697382 - Effect of Daily Steps on Fat Metabolism N/A
Completed NCT03241121 - Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome N/A
Completed NCT04509206 - Virtual Teaching Kitchen N/A
Completed NCT05124847 - TREating Pediatric Obesity N/A